MFDS — authorised 25 October 2022
- Marketing authorisation holder: JANSSEN BIOTECH
- Status: likely_approved
🇰🇷 Bcmaxcd3 in South Korea
MFDS authorised Bcmaxcd3 on 25 October 2022
Marketing authorisation
Bcmaxcd3 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Bcmaxcd3 approved in South Korea?
Yes. MFDS authorised it on 25 October 2022.
Who is the marketing authorisation holder for Bcmaxcd3 in South Korea?
JANSSEN BIOTECH holds the South Korean marketing authorisation.